Liquidia (NASDAQ:LQDA) Releases Earnings Results, Misses Estimates By $0.07 EPS

Liquidia (NASDAQ:LQDA) issued its quarterly earnings data on Wednesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07), Zacks reports. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%.

Liquidia Trading Down 0.3 %

Shares of NASDAQ LQDA opened at $14.74 on Wednesday. Liquidia has a 12 month low of $8.26 and a 12 month high of $16.99. The company has a 50 day simple moving average of $14.62 and a two-hundred day simple moving average of $12.10. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -9.04 and a beta of 0.07.

Insider Buying and Selling at Liquidia

In other Liquidia news, CFO Michael Kaseta sold 23,370 shares of Liquidia stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the sale, the chief financial officer now directly owns 401,755 shares in the company, valued at approximately $4,732,673.90. The trade was a 5.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Rajeev Saggar sold 2,445 shares of Liquidia stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total transaction of $31,785.00. Following the sale, the insider now owns 267,943 shares of the company’s stock, valued at approximately $3,483,259. The trade was a 0.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,245 shares of company stock worth $843,326. Company insiders own 30.10% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on LQDA. Needham & Company LLC reissued a “buy” rating and set a $19.00 target price on shares of Liquidia in a research report on Thursday, January 9th. Wells Fargo & Company began coverage on shares of Liquidia in a research report on Friday, December 20th. They set an “overweight” rating and a $20.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $25.38.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).